Regeneron Bets $100M That Mammoth s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
Regeneron Pharmaceuticals is paying $250 million cash to acquire Checkmate Pharmaceuticals, a clinical-stage biotech developing drugs that activate the innate immune system. The biotech’s lead drug candidate is currently in pivotal testing in melanoma.
Cure the Causes founder Dr. Christina Rahm warned the public that more bioweapons are coming after the Wuhan coronavirus (COVID-19). Prior to delving into holistic medicine, Rahm worked for [.]
Regeneron s Covid Antibody Treatment Drives Surge in Sales bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.